

**VONJO  
(pacritinib)**

## **Pre - PA Allowance**

None

---

## **Prior-Approval Requirements**

**Age** 18 years of age and older

### **Diagnoses**

Patient must have **ONE** of the following:

1. Primary myelofibrosis
2. Secondary myelofibrosis
3. Post-polycythemia vera myelofibrosis
4. Post-essential thrombocythemia myelofibrosis

**AND ALL** of the following:

- a. Patient is considered intermediate risk or high-risk
- b. Platelet count < 50 x 10<sup>9</sup>/L
- c. Prescriber agrees to perform a CBC, coagulation testing, and a baseline ECG prior to starting Vonjo
- d. Prescriber agrees to counsel patient to discontinue Vonjo 7 days prior to elective surgery due to the risk of hemorrhage

## **Prior - Approval Limits**

**Quantity** 360 capsules per 90 days

**Duration** 6 months

---

## **Prior – Approval *Renewal* Requirements**

**Age** 18 years of age and older

### **Diagnoses**

Patient must have **ONE** of the following:

1. Primary myelofibrosis
2. Secondary myelofibrosis
3. Post-polycythemia vera myelofibrosis



**BlueCross  
BlueShield**

Federal Employee Program.

**VONJO  
(pacritinib)**

4. Post-essential thrombocythemia myelofibrosis

**AND ALL** of the following:

- a. Patient has had symptomatic improvement
- b. Platelet count  $< 50 \times 10^9/L$
- c. Prescriber agrees to counsel patient to discontinue Vonjo 7 days prior to elective surgery due to the risk of hemorrhage

**Prior - Approval *Renewal* Limits**

Same as above